A Study of SHR-1826 Monotherapy or in Combination With Immunotherapy in the Treatment of Advanced Hepatocellular Cancer
The study was designed to evaluate the efficacy and safety of SHR-1826 monotherapy or in combination with immunotherapy in the treatment of advanced hepatocellular cancer patients.
Hepatocellular Cancer
DRUG: SHR-1826|DRUG: SHR-1826 and immunotherapy combination therapy
Objective Response Rate (ORR) by RECIST V1.1, The ORR is defined as complete remission (CR) rate + partial remission (PR) rate by RECIST V1.1., up 2 years
Objective Response Rate (ORR) by mRECIST, The ORR is defined as complete remission (CR) rate + partial remission (PR) rate by mRECIST., up 2 years|Disease control rate (DCR) by RECIST V1.1, The DCR is defined as complete remission (CR) rate + partial remission (PR) rate + stable disease (SD)., up 2 years|Progression-free survival (PFS), The PFS is defined as Time from the date of enrollment to of disease., up 2 years|Overall survival (OS), The OS is defined as time from the date of enrollment to data of death from any cause, or date of lost follow-up, whichever comes first, and otherwise censored at time last known alive., up 2 years
The study was designed to evaluate the efficacy and safety of SHR-1826 monotherapy or in combination with immunotherapy in the treatment of advanced hepatocellular cancer patients.